PYC - General Discussion, page-696

In a clinical sense, PYC continues to power forward with positive and ongoing progress for its strategy working towards achieving FDA approval on its nominated pipeline, (2 x candidates now in human trials, and 2 x candidates targeting commencement in human trials soon). Big tick, IMO

But…

As an ASX listed stock, PYC is subject to all sorts of ASX machinations. Namely, nothing ever goes up, (price wise), in a straight line, there are always pullbacks for numerous reasons. Some participants, shareholders, have a bias towards short term opportunities whereas others have a bias towards the longer term, these preferences appear to be based on perceived opportunity and risk appetite/tolerances. Emotions tend to be strong when it comes to money. FEAR, of losing money or of missing out on an opportunity to make money are massive factors.

So where are we now, price wise?

PYC SP price hit $2.10, an intraday high on 22^nd October, subsequently 7 x Price Sensitive announcements have been released via ASX. See below.

As at 10^th December, PYC SP closed at $1.46. I can certainly see some possible hesitations, such as PYC funding sources, scenarios for BD partnerships, ASX typical consolidation woes…

Is this pullback done yet? Is the risk more to the upside or downside now?

Just some personal musings... best wishes and DYOR

--------------------------------------------------------------------------

ASX Price Sensitive announcements since 22nd Oct, 2024
--------------------------------------------------------------------------
Interim update on progress in RP11, Repeat Dose trial22^nd Oct

Quarterly Activities/Appendix 4c Cash Flow Report25^th Oct

First ADOA patient dosed in clinical trial1^st Nov

RP11 SRC (Safety Review Committee), approves

escalation to final patient cohort5^th Nov

Consolidation/Split11^th Nov

Presentation of RP11 clinical trail data at APVRS22^nd Nov

PYC to progress Kidney drug candidate into human trials 27^th Nov

-----------------------------------------------------------------------------------------------